June Kim

About June Kim

Dr. June H. Lee is an experienced physician-scientist and biopharmaceutical executive known for her deep expertise in clinical development, biotech strategy, and public-company governance. She has served as an independent director on the Board of Directors of Abivax since July 2023, where she is Chair of the Nomination and Compensation Committee. Her appointment strengthened Abivax’s strategic oversight at an important stage in the advancement of its Phase 3 clinical program. Before joining Abivax, June Lee was a Venture Partner at 5AM Ventures. She previously founded Esker Therapeutics, where she served as Chief Executive Officer until September 2021. Earlier, she held senior leadership roles at MyoKardia, including Executive Vice President, Chief Development Officer and Chief Operating Officer, helping build a world-class development organization that was later acquired by Bristol Myers Squibb for $13.1 billion in November 2020. At MyoKardia, she also helped advance mavacamten, the company’s lead program, through regulatory approval. Prior to that, Dr. Lee worked at the University of California, San Francisco, where she led the Catalyst program and oversaw strategy and operations supporting translational research. She also held leadership responsibilities at Genentech, directing early clinical development activities across cardiovascular, metabolic, infectious, and respiratory disease areas. This background gives her a strong track record in identifying, advancing, and scaling innovative therapeutic assets. At Abivax, her profile is especially relevant for a listed late-stage biotechnology company developing obefazimod for chronic inflammatory diseases. Her combination of development, governance, capital allocation, and value-creation experience is well suited to supporting strategic execution, financial discipline, and preparations for key regulatory and commercial milestones.